A qualitative investigation of antiretroviral therapy among injection drug users

AIDS and Behavior

Volumn 7, Issue 1, 2003, Pages 87-100

  Pach III, Alfred ^a   Cerbone, Felicia Gray ^a   Gerstein, Dean R ^a  

^a University of Chicago   (United States)

Author keywords

Antiretroviral therapy; HIV AIDS; Injection drug use

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; FATALITY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HEALTH SURVEY; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; INTRAVENOUS DRUG ABUSE; LIFE EXPECTANCY; LONGITUDINAL STUDY; MALE; PARESTHESIA; PRURITUS; QUALITATIVE ANALYSIS; QUALITY OF LIFE; UNITED STATES; VERTIGO;

ADULT; ANTI-RETROVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HIV SEROPOSITIVITY; HUMANS; MALE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 0037948851     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022517608578     Document Type: Article

References (73)

1. American Medical Association (2001). HIV and heroin interactions. Journal of the American Medical Association, 286, 295.
2. Bangsberg, D., and Moss, A. (1999). When should we delay highly active antiretroviral therapy? Journal of General Internal Medicine, 14, 464-468.
3. Bangsberg, D., Tulsky, J., Hecht, F., and Moss, A. (1997). Protease inhibitors in the homeless. Journal of the American Medical Association, 278, 63-65.
4. Bassetti, S., Battegay, M., Furrer, H., Rickenbach, M., Flepp, M., Kaiser, L., Telenti, A., Vernazza, P., Bernasconi, E., and Sudre, P. (1999). Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 21, 114-119.
5. Bassetti, S., Battegay, M., and Sudre, P. (2000). Access to antiretroviral therapy. Journal of the American Medical Association, 283, 883-884.
6. Broadhead, R., Heckathorn, D., Grund, J., Stern, S., and Anthony. D. (1995). Drug users versus outreach workers in combating AIDS: Preliminary results of peer-driven intervention. Journal of Drug Issues, 25, 531-564.
7. Carlson, R., Wang, J., Siegal, H., Falck, R., and Guo, J. (1994). An ethnographic approach to targeted sampling: Problems and solutions in AIDS prevention research among injection drug users and crack cocaine users. Human Organization, 52, 279-286.
8. Celentano, D. D., Vlahov, D., Cohn, S., Shadle, V. M., Obasanjo, O., and Moore, R. D. (1998). Self-reported antiretroviral therapy in injection drug users. Journal of the American Medical Association, 280, 544-546.
9. Centers for Disease Control and Prevention. (1998). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Mobidity and Mortality Weekly Reports, 47, 43-82.
10. Centers for Disease Control and Prevention. (2000). HIV/AIDS among racial/ethnic minority men who have sex with men United States 1989-1998. Mobidity and Mortality Weekly Reports, 49, 4-11.
11. Cherubin, C., and Sapira, J. (1993). The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Annals of Internal Medicine, 119, 1017-1028.
12. Chesney, M., Ickovics, J., Hecht, F., and Sikipa, G. (1999). Adherence: A necessity for successful HIV combination therapy. AIDS, 13, 271-278.
13. Connors, M. (1995). The politics of marginalization: The appropriation of AIDS prevention messages among injection drug users. Culture, Medicine and Psychiatry, 19, 425-452.
14. Crespo-Fierro. M. (1997). Compliance/adherence and care management in HIV disease. Journal of the Association of Nurses in AIDS Care, 8, 43-54.
15. Crystal, S. (1992). Health-care barriers and utilization patterns among intravenous-drug users with HIV disease. AIDS and Public Policy Journal, 7, 187-198.
16. Crystal, S., Sambamoorthi, U., and Merzel, C. (1995). The diffusion of innovation in AIDS treatment: Zidovudine use in two New Jersey cohorts. Health Services Research, 30, 593-614.
17. Deeks, S. G., Grant, R. M., Beatty, G. W., Horton, D., Demar, J., and Eastman, S. (1998). Activity of ritonavir plus saquinavircontaining regimen with virologic evidence of indinavir or ritonavir failure. AIDS, 12, 97-102.
18. Demas, P., Schoenbaum, E., Hirky, A., Wills, T., Doll, L., Hartel, D., and Klein, R. (1998). The relationship of HIV treatment acceptance and adherence to psychosocial factors among injecting drug users. AIDS and Behavior, 2, 283-292.
19. Emerson, R., Fretz, R., and Shaw, L. (1995). Writing ethnographic fieldnotes. Chicago: University of Chicago Press.
20. Fee, E., and Krieger, N. (1993). Thinking and rethinking AIDS: Implications for health policy. International Journal of Health Services, 23, 323-346.
21. Ferzacca, S. (2000). "Actually, I don't feel that bad": Managing diabetes and the clinical encounter. Medical Anthropology Quarterly, 14, 28-50.
22. Friedman, P., McCullough, D., and Saitz, R. (2001). Screening and intervention for illicit drug abuse: A national survey of primary care physicians and psychiatrists. Archives of Internal Medicine, 161, 248-251.
23. Friedman, S., de Jong, W., and Des Jarlais, D. (1988). Problems and dynamics of organizing intravenous drug users for AIDS prevention. Health Education Research, 3, 49-57.
24. Friedman, S., Neaigus, A., Jose, B., Curtis, R., Goldstein, M., Sotheran, J., Wenston, J., Latkin, C., and Des Jarlais, D. (1997). Network and sociohistorical approaches to the HIV epidemic among drug injectors. In J. Catalan, L. Sherr, and B. Hedge (Eds.), The impact of AIDS: Psychological and social aspects of HIV infection (pp. 89-113). Amsterdam: Harwood.
25. Friedman, S., Wainberg, M., and Drucker, E. (1998a). Therapeutic ethics and communities at risk in the presence of potential mutation to resistant strains to HIV antiviral medications. AIDS, 12, 2089-2093.
26. Friedman, S., Jose, B., Neaigus, A., Goldstein, M., Mota, P., Curtis, R., Ildefonso, G., and DesJarlais, D. (1998b). Multiple racial ethnic subordination and HIV among drug injectors. In M. Singer (Ed.), The political economy of AIDS (pp. 105-127). Amityville, NY: Baywood.
27. Friedman, S., Curtis, R., Neaigus, A., Jose, B., and Des Jarlais, D. (1999). Social networks, drug injectors' lives and HIV/AIDS. New York: Kluwer Academic/Plenum.
28. Hartnoll, R. (1992). Research and the help-seeking process. British Journal of Addiction, 87, 429-437.
29. Hassin, J. (1994). Living a responsible life: The impact of AIDS on the social identity of intravenous drug users. Social Science and Medicine, 39, 391-400.
30. Heckathorn, D. (1997). Respondent-driven sampling: A new approach to the study of hidden populations. Social Problems, 44, 174-199.
31. Hoffmann, J. P., Su, S. S., and Pach, A. (1997). Changes in network characteristics and HIV risk behavior among injection drug users. Drug and Alcohol Dependence, 46, 41-51.
32. Holmberg, S. (1996). The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. American Journal of Public Health, 85, 642-654.
33. Hunt, L., Jordan, B., Irwin, S., and Browner, C. (1989). Compliance and the patient's perspective: Controlling symptoms in everyday life. Culture, Medicine and Psychiatry, 13, 315-334.
34. Inciardi, J., Martin, S., and Scarpitti, F. (1994). Appropriateness of assertive case management for drug-involved prison releasees. Journal of Case Management, 3, 145-149.
35. Johnson, R. A., Gerstein, D. R., Pach, A., Cerbone, F. G., and Brown, J. (2002). HIV risk behaviors in drug injector networks: Iimplications of injection partner mixing and partnership characteristics. Addiction, 97, 1011-1024.
36. Jones, J. H. (1993). Bad blood: The Tuskegee syphilis experiment. New York: Free Press.
37. Karon, J. M., Fleming, P. L., Steketee, R. W., De Cock, K. M. (2001). HIV in the United States at the Turn of the Century: An epidemic in Transition. American Journal of Public Health, 91, 1060-1068.
38. Kissinger, P., Cohen, D., Brandon, W., Rice, J., Morse, A., and Clark, R. (1995). Compliance with public sector HIV medical care. Journal of the National Medical Association, 87, 19-24.
39. Klovdahl, A. (1989). Urban social networks: Some methodological problems and possibilities. In M. Kochen (Ed.), The small world (pp. 176-210). Norwood, NJ: Ablex.
40. Leukefeld, C., Logan, T., Martin, S., Durvis, R., and Farabee, D. (1998). A health services use framework for drug-abusing offenders. American Behavioral Scientist, 41, 1123-1135.
41. Maisels, L., Steinberg, J., and Tobias, C. (2001). An investigation of why eligible patients do not receive HAART. AIDS Patient Care and STDs, 15, 185-191.
42. Mayer, K. (1999). Combination antiretroviral chemotherapy: Shifting paradigms and evolving praxis. In D. Ostrow and S. Kalichman (Eds.), Psychosocial and public health impacts of new HIV therapies (pp. 1-26). New York: Kluwer Academic/ Plenum.
43. McLaughlin, D. C., McKenna, H., and Leslie, J. C. (2000). The perceptions and aspirations illicit drug users hold toward health care staff and the care they receive. Journal of Psychiatric and Mental Health Nursing, 7, 435-441.
44. Mocroft, A., Madge, S., Johnson, A., Lazzarin, A., Clumeck, N., Goebel, F. D., Viard, J. P., Gatell, J., Blaxhult, A., and Lundgren, J. (1999). A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy, response and survival. Journal of Acquired Immune Deficiency Syndromes, 22, 369-378.
45. Mostashari, F., Riley, E., Selwyn, P., and Altice, F. (1998). Acceptance and adherence of antiretroviral therapy among HIV-infected women in a correctional facility. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 18, 341-348.
46. O'Connor, P., Molde, S., Henry, S., Shockcor, W., and Schottenfeld, R. (1992). Human immunodeficiency virus infection in intravenous drug users: A model for primary care. American Journal of Medicine, 93, 382-386.
47. O'Connor, P., Selwyn, P., and Schottenfeld, R. (1994). Medical care for injection drug users with human immunodeficiency virus infection. New England Journal of Medicine, 331, 450-459.
48. Palella, F., Delaney, K., Moorman, A., Loveless, M., Fuhrer, J., Satten, G., Ashman, D., and Holmberg, S. (1998). Declining morbidity and mortality among patients with advanced HIV infection. New England Journal of Medicine, 338, 853-860.
49. Pequegnat, W., and Stover, E. (1999). Behavioral research needs and challenges of new treatments: AIDS as a chronic illness. In D. Ostrow and S. Kalichman (Eds.), Psychosocial and public health impacts of new HIV therapies (pp. 183-191). New York: Kluwer Academic/Plenum.
50. Pescosolido, B., Wright, E. R., Alegria, M., and Vera, M. (1998). Social networks and patterns of use among the poor with mental health problems in Puerto Rico. Medical Care, 36, 1057-1072.
51. Piette, J., Mor, V., Mayer, K., Zierler, S., and Wachtel, T. (1992). The effects of immune status and race on health service use among people with HIV disease. American Journal of Public Health, 83, 510-514.
52. Rabkin, J., and Chesney, M. (1999). Treatment adherence to HIV medications: The Achilles heel of the new therapeutics. In D. Ostrow and S. Kalichman (Eds.), Psychosocial and public health impacts of new HIV therapies (pp. 61-79). New York: Kluwer Academic/Plenum.
53. Rhodes, T. (1994). HIV, outreach, peer education and community change. Health Education Journal, 53, 92-99.
54. Roberts, K. (2000). Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimen. AIDS Patient Care and STDs, 14, 155-168.
55. Rockwell, R., Friedman, S., Sotheran, J., and Des Jarlais, D. (1998). Medical access for injecting drug users. In M. Singer (Ed.), The political economy of AIDS (pp. 131-147). Amityville, NY: Baywood.
56. Ruiz, L., Martinez-Picado, J., Romeru, J., Paredes, R., Mohd, K., Marfil, S., Negrado, E., Sierra, G., Tural, L., and Cloet, B. (2000). Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression. AIDS, 14, 397-403.
57. Selwyn, P., Alcabes, P., Hartel, D., Buono, D., Schoenbaum, E., Klein, R., Daveny, K., and Friedland, G. (1992). Clinical manifestations and predictors of diseases progression in drug users with human immunodeficiency virus infection. New England Journal of Medicine, 327, 1697-1703.
58. Shapiro, M., Morton, C., McCaffrey, D., Senterfitt, J., Fleishman, J., Perlman, J., Athey, L., Keesey, J., Goldman, D., Berry, S., and Bozzette, S. (1999). Variations in the care of HIV-infected adults in the United States. Journal of the American Medical Association, 281, 2305-2315.
59. Singer, M. (1998). Forging a political economy of AIDS. In M. Singer (Ed.), The political economy of AIDS (pp. 3-31). Amityville, NY: Baywood.
60. Solomon, L., Frank, R., Vlahov, D., and Astemborski, J. (1991). Utilization of health services in a cohort of intravenous drug users with known HIV-1 serostatus. American Journal of Public Health, 81, 1285-1290.
61. Stein, M. A., O'Sullivan, P. S., Ellis, P., Perrin, H., and Wartenberg, A. (1993). Utilization of medical services by drug abusers in detoxification. Journal of Substance Abuse, 5, 187-193.
62. Strathdee, S. A., Palepu, A., Cornelisse, P. G., Yip, B., O'Shaughnessy, M. V., Montaner, J. S., Schechter, M. T., and Hogg, R. S. (1998). Barriers to use of free antiretroviral therapy in injection drug users. Journal of American Medical Association, 280, 547-549.
63. Strauss, A., Corbin, J., Fagerhaugh, S., Glaser, B., Maines, D., Suczek, B., and Wiener, C. (1984). Chronic illness and the quality of life. St. Louis: Mosby.
64. Thomas, S., and Quinn, S. (1991). The Tuskegee Syphilis Study, 1932 to 1972: Implications for HIV education and AIDS risk education programs in the Black community. American Journal of Public Health, 81, 1498-1504.
65. Trostle, J., Hauser, A., and Susser, I. (1983). The logic of noncompliance: Management of epilepsy from the patient's point of view. Culture, Medicine and Society, 7, 35-56.
66. U.S. Public Health Service. (1997). HIV prevention bulletin: Medical advice for persons who inject illicit drugs. Washington, DC: U.S. Government Printing Office [Available at http:// www.cdc.gov/nchstp/hiv___aids/pubs/hiv/prev.txt].
67. van der Werf, M. J., Schnikel, J., van Santen, G., Vergouwe, I., Wix, R., and van Ameijden, E. (1999). Highly active antiretroviral therapy among drug users in Amsterdam: Self-perceived reasons for not receiving therapy. AIDS, 13, 1280-1281.
68. Wainberg, M. A., and Friedland, G. (1998). Public health implications of antiretroviral therapy and HIV drug resistance. Journal of the American Medical Association, 279, 1977-1983.
69. Waterston, A. (1997). Anthropological research and the politics of HIV prevention: Towards a critique of policy and priorities in the age of AIDS. Social Science and Medicine, 44, 1381-1391.
70. Watters, J., and Biernacki, P. (1975). Targeted sampling: Options for the study of hidden populations. Social Problems, 36, 416-430.
71. Weidle, P., Holmberg, S., and DeCock, K. (1999). Changes in HIV and AIDS epidemiology from new generation antiretroviral therapy. AIDS, 13, 61-68.
72. Weissman, G., Melchior, L., Huba, G., Altice, F., Booth, R., Cottler, L., Genser, S., Jones, A., McCarthy, S., Needle, R., and Smerck, G. (1995). Women living with substance abuse and HIV disease: Medical care access issues. Journal of American Medical Women's Association, 50, 115-120.
73. White House Fact Sheet. (1998). President Clinton announces new racial and ethnic health disparities initiative. Internet Announcement, HHS Press Office, February 21, 1998 [Available at http://www.raceandhealth.hhs.gov/sidebars/sbinitPres.htm].